XETRA - Delayed Quote EUR

Formycon AG (FYB.DE)

24.35
-0.20
(-0.81%)
At close: May 9 at 5:35:22 PM GMT+2
Currency in EUR All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
69,674
69,674
77,696
42,497
36,613
Cost of Revenue
54,840
54,840
54,391
30,426
26,503
Gross Profit
14,834
14,834
23,305
12,071
10,110
Operating Expense
38,379
38,379
23,674
29,800
24,110
Operating Income
-23,545
-23,545
-369
-17,729
-14,000
Net Non Operating Interest Income Expense
2,488
2,488
2,722
159
-171
Pretax Income
-144,253
-144,253
79,070
36,596
-14,207
Tax Provision
-18,582
-18,582
3,275
604
-917
Net Income Common Stockholders
-125,672
-125,672
75,795
35,992
-13,290
Diluted NI Available to Com Stockholders
-125,672
-125,672
75,795
35,992
-13,290
Basic EPS
-7.18
--
4.76
2.62
-1.20
Diluted EPS
-7.18
--
4.72
2.59
-1.20
Basic Average Shares
17,491.81
--
15,915.79
13,715.22
11,042.64
Diluted Average Shares
17,633.37
--
16,048.62
13,883.87
11,170
Total Operating Income as Reported
-23,543
-23,543
-369
-17,728
-14,000
Total Expenses
93,219
93,219
78,065
60,226
50,613
Net Income from Continuing & Discontinued Operation
-125,672
-125,672
75,795
35,992
-13,290
Normalized Income
97,744.74
97,744.74
-16,392.69
58,388.16
-13,290.94
Interest Income
3,595
3,595
2,817
302
2
Interest Expense
1,089
1,089
80
125
39
Net Interest Income
2,488
2,488
2,722
159
-171
EBIT
-143,164
-143,164
79,150
36,721
-14,168
EBITDA
-4,099
-4,099
81,037
38,583
-12,556
Reconciled Cost of Revenue
54,840
54,840
54,391
30,426
26,503
Reconciled Depreciation
139,065
139,065
1,887
1,862
1,612
Net Income from Continuing Operation Net Minority Interest
-125,672
-125,672
75,795
35,992
-13,290
Total Unusual Items Excluding Goodwill
-108,087
-108,087
96,171
-22,772
1
Total Unusual Items
21,166
21,166
96,171
-22,772
1
Normalized EBITDA
-25,265
-25,265
-15,134
61,355
-12,557
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
-13,923.26
-13,923.26
3,983.31
-375.84
0.06
12/31/2021 - 1/4/2011

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

VVY.AS Vivoryon Therapeutics N.V.
1.7640
+0.11%
 
7V0.DE Darwin AG
28.20
0.00%
 
BIO.DE Biotest Aktiengesellschaft
42.60
0.00%
 
473A.SG Adaptimmune Therapeutics PLC
0.2620
0.00%
 
NVV1.DE Novavax, Inc.
7.85
-0.53%
 
9VC.DE Atai Life Sciences N.V.
1.2020
0.00%
 
BIO3.DE Biotest Aktiengesellschaft
30.00
0.00%
 
88Q.DE 4basebio PLC
13.00
+0.78%
 
3G0.BE Altimmune Inc
4.9370
+1.38%
 
MARI.VI Marinomed Biotech AG
12.25
+0.41%